Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

During the four years of the RABYD-VAX project, the researchers also hope to gain novel insights into the PLLAV technology and its potential to target indications besides rabies. Credit: Courtest of the RABYD-VAX Consortium